Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue , 2014, Pages 11-32

  Armuzzi, A ^a   Lionetti, P ^b   Blandizzi, C ^c   Caporali, R ^d   Chimenti, S ^e   Cimino, L ^f   Gionchetti, P ^g   Girolomoni, G ^h   Lapadula, G ⁱ   Marchesoni, A ^j   Marcellusi, A ^e   Mennini, F S ^e   Salvarani, C ^k   Cimaz, R ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f Ophthalmology Unit   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF VERONA   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j G Pini Orthopaedic Institute   (Italy)

^k S MARIA NUOVA HOSPITAL   (Italy)

more..

Author keywords

anti TNF therapy; immune mediated disorders; Tumour necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COMPLEX FORMATION; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DEMYELINATION; DISEASE EXACERBATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRANULOMATOUS INFLAMMATION; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFECTION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; INFUSION RELATED REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; ULCERATIVE COLITIS; VASCULITIS; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; IMMUNOLOGY; INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900836271     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/03946320140270S102     Document Type: Review

References (110)

1. Firestein G.S., Corr M., Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl 2005; 73: 8-13; discussion 29-30.
2. Robinson D. Jr., Hackett M., Wong J., Kimball A.B., Cohen R., Bala M., Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: An exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006; 22: 989-1000.
3. Yeh S., Karne N. K., Kerkar S. P., et al.Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009; 116: 981-89 e1.
4. Cihakova D., Rose N.R., Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008; 99: 95-114.
5. Lakomek H.J., Krause A., [Treat-to-target (T2T) from the perspective of inpatient rheumatology]. Z Rheumatol 2011; 70: 656-63.
6. Callhoff J., Weiss A., Zink A., Listing J., Impact of biologic therapy on functional status in patients with rheumatoid arthritis-a meta-analysis. Rheumatology (Oxford) 2013; 52: 2127-2135.
7. Kuek A., Hazleman B.L., Ostor A.J., Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution. Postgrad Med J 2007; 83: 251-60.
8. Blonski W., Buchner A.M., Lichtenstein G.R., Inflammatory bowel disease therapy: Current state-of-the-art. Curr Opin Gastroenterol 2011; 27: 346-57.
9. Furst D.E., Keystone E.C., Braun J., et al.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012; 71 Suppl 2: i2-45.
10. Abuzakouk M., Feighery C., Jackson J., Tumour necrosis factor blocking agents: A new therapeutic modality for inflammatory disorders. Br J Biomed Sci 2002; 59: 173-9.
11. Bijlsma J.W., Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice. Pol Arch Med Wewn 2010; 120: 347-53.
12. Orlando A., Armuzzi A., Papi C., et al.The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011; 43: 1-20.
13. Watson K., Hyrich K., The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy. Musculoskeletal Care 2003; 1: 58-64.
14. Woof J.M., Burton D.R., Human antibody-Fc receptor interactions illuminated by crystal structures. Nat Rev Immunol 2004; 4: 89-99.
15. Thalayasingam N., Isaacs J.D., Anti-TNF therapy. Best practice & research Clinical rheumatology 2011; 25: 549-67.
16. Albanesi M., Daeron M., The interactions of therapeutic antibodies with Fc receptors. Immunol Lett 2012; 143: 20-7.
17. Shealy D., Cai A., Staquet K., et al.Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010: 2.
18. Rau R., Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials. Ann Rheum Dis 2002; 61 Suppl 2: ii70-3.
19. Maini R., St Clair E.W., Breedveld F., et al.Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
20. Haraoui B., Bykerk V., Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2007; 3: 99-105.
21. Chimenti M.S., Saraceno R., Chiricozzi A., Giunta A., Chimenti S., Perricone R., Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther 2013; 7: 339-48.
22. Taylor P.C., Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 2010; 10: 308-15.
23. Benucci M., Saviola G., Manfredi M., Sarzi-Puttini P., Atzeni F., Tumor necrosis factors blocking agents: Analogies and differences. Acta Biomed 2012; 83: 72-80.
24. Rigby W.F., Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 2007; 3: 227-33.
25. Mewar D., Wilson A.G., Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011; 162: 785-91.
26. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P., Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008; 117: 244-79.
27. Malottki K., Barton P., Tsourapas A., et al.Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: A systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-278.
28. Orme M.E., Macgilchrist K.S., Mitchell S., Spurden D., Bird A., Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: Analysis of American College of Rheumatology criteria scores 20, 50, and 70. Biologics 2012; 6: 429-64.
29. Devine E.B., Alfonso-Cristancho R., Sullivan S.D., Effectiveness of biologic therapies for rheumatoid arthritis: An indirect comparisons approach. Pharmacotherapy 2011; 31: 39-51.
30. Aaltonen K.J., Virkki L.M., Malmivaara A., Konttinen Y.T., Nordstrom D.C., Blom M., Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7: e30275.
31. Gallego-Galisteo M., Villa-Rubio A., Rey E. Alegredel, Marquez-Fernandez E., Ramos-Baez J.J., Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther 2012; 37: 301-7.
32. Mandema J.W., Salinger D.H., Baumgartner S.W., Gibbs M.A., A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 2011; 90: 828-35.
33. Fajri D.W., Brand C.A., Dharmage S.C., Martin B.J., Buchanan R.R., Schachna L., What factors determine patients' preference for tumour necrosis factor inhibitors in ankylosing spondylitis? Clin Rheumatol 2009; 28: 599-602.
34. Scarpato S., Antivalle M., Favalli E.G., et al.Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford) 2010; 49: 289-94.
35. Chilton F., Collett R.A., Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
36. Allen P.B., Lindsay H., Tham T.C., How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010; 10: 1.
37. Spinelli F.R., Valesini G., Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Clin Exp Rheumatol 2013; 31: 954-963.
38. van Schouwenburg P.A., Rispens T., Wolbink G.J., Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72.
39. Garces S., Antunes M., Benito-Garcia E., da Silva J.C., Aarden L., Demengeot J., A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2013 (Epub ahead of print).
40. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V., Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Jama 2006; 295: 2275-85.
41. Ding T., Ledingham J., Luqmani R., et al.BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49: 2217-9.
42. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Galloway J., Ustianowski A., Symmons D.P., Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
43. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., Lohr K.N., The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 2006; 33: 2398-408.
44. Onel K.B., Onel K., Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders. Arthritis Care Res (Hoboken) 2010; 62: 1024-8.
45. Gisbert J.P., Chaparro M., Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 1426-38.
46. Nam J.L., Winthrop K.L., van Vollenhoven R.F., et al.Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
47. Pierreisnard A., Issa N., Barnetche T., Richez C., Schaeverbeke T., Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint Bone Spine 2013; 80: 386-92.
48. Kuriya B., Arkema E.V., Bykerk V.P., Keystone E.C., Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: A meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69: 1298-304.
49. Jani M., Barton A., Warren R.B., Griffiths C.E., Chinoy H., The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53: 213-22.
50. Andrisani G., Gremese E., Guidi L., et al.Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis. In press 2013.
51. Murdaca G., Colombo B.M., Puppo F., Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Bare) 2011; 47: 277-88.
52. Schmitz S., Adams R., Walsh C.D., Barry M., FitzGerald O., A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: A Bayesian approach. Ann Rheum Dis 2012; 71: 225-30.
53. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
54. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al.The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37.
55. Lovell D.J., Ruperto N., Goodman S., et al.Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20.
56. van der Heijde D., Kivitz A., Schiff M. H., et al.Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
57. van der Heijde D., Schiff M. H., Sieper J., et al.Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: Long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68: 922-9.
58. Mease P.J., Gladman D.D., Ritchlin C.T., et al.Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279-89.
59. Mease P.J., Ory P., Sharp J.T., et al.Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68: 702-9.
60. Menter A., Tyring S.K., Gordon K., et al.Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
61. Gordon K., Papp K., Poulin Y., Gu Y., Rozzo S., Sasso E.H., Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
62. Saurat J.H., Stingl G., Dubertret L., et al.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-66.
63. Colombel J.F., Sandborn W.J., Rutgeerts P., et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007; 132: 52-65.
64. Schreiber S., Reinisch W., Colombel J.F., et al.Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-21.
65. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al.Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
66. Rutgeerts P., Van Assche G., Sandborn W. J., et al.Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11 e2.
67. Sandborn W.J., van Assche G., Reinisch W., et al.Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65 e1-3.
68. Sandborn W.J., Colombel J.F., D'Haens G., et al.One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
69. Garcia-Bosch O., Gisbert J. P., Canas-Ventura A., et al.Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013; 7: 717-722.
70. D'Haens G., Reinisch W., Satsangi J., et al.PYRAMID Registry: Observational Study of Adalimumab in Crohn's Disease: Results at Year 3 [poster P1140]. The American College of Gastroenterology Annual Scientific Meeting Washington, DC 2011.
71. Armuzzi A., Biancone L., Daperno M., et al.Adalimumab In Active Ulcerative Colitis: A "Real-Life" Observational Study. Dig Liver Dis 2013; 45: 738-43.
72. Afif W., Leighton J.A., Hanauer S.B., et al.Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302-7.
73. Baert F., Glorieus E., Reenaers C., et al.Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J Crohns Colitis 2013; 7: 154-60.
74. Kleinert S., Tony H.P., Krause A., et al.Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: Data from a German noninterventional observational study. Rheumatol Int 2012; 32: 2759-67.
75. Bombardieri S., Ruiz A.A., Fardellone P., et al.Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-9.
76. Burmester G.R., Mariette X., Montecucco C., et al.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
77. Papp K., Crowley J., Ortonne J.P., et al.Adalimumab for moderate to severe chronic plaque psoriasis: Efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-41.
78. Taniguchi T., Noda S., Takahashi N., Yoshimura H., Mizuno K., Adachi M., An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: A possible new therapeutic option for good responders to the initial induction treatment. J Eur Acad Dermatol Venereol 2013; 27: 1444-1447.
79. Zavada J., Dixon W.G., Askling J., Launch of a checklist for reporting longitudinal observational drug studies in rheumatology: A EULAR extension of STROBE guidelines based on experience from biologics registries. Ann Rheum Dis 2014; 73: 628.
80. Caporali R., Pallavicini F.B., Filippini M., et al.Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmun Rev 2009; 8: 274-80.
81. Mariette X., Gottenberg J.E., Ravaud P., Combe B., Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries. Rheumatology (Oxford) 2011; 50: 222-9.
82. de Punder Y.M., Fransen J., Kievit W., Houtman P.M., Visser H., van de Laar M.A., van Riel P.L., The prevalence of clinical remission in RA patients treated with anti-TNF: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2012; 51: 1610-7.
83. van Dartel S.A., Fransen J., Kievit W., et al.Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: Results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013; 72: 895-900.
84. van Dartel S.A., Fransen J., Kievit W., et al.Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: A cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) 2013; 52: 1052-7.
85. Hetland M.L., Christensen I.J., Tarp U., et al.Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
86. Ornbjerg L.M., Ostergaard M., Boyesen P., et al.Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: Results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2013; 72: 57-63.
87. Atzeni F., Sarzi-Puttini P., Botsios C., et al.Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012; 12: 225-9.
88. Iannone F., Gremese E., Atzeni F., et al.Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: An appraisal of predictors. J Rheumatol 2012; 39: 1179-84.
89. Furst D.E., Pangan A.L., Harrold L.R., Chang H., Reed G., Kremer J.M., Greenberg J.D., Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken) 2011; 63: 856-64.
90. Greenberg J.D., Reed G., Decktor D., et al.A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: Results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
91. Markenson J.A., Gibofsky A., Palmer W.R., Keystone E.C., Schiff M.H., Feng J., Baumgartner S.W., Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: Observations from the RADIUS registry. J Rheumatol 2011; 38: 1273-81.
92. Hyrich K.L., Watson K.D., Isenberg D.A., Symmons D.P., The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford) 2008; 47: 1441-3.
93. Lunt M., Watson K.D., Dixon W.G., Symmons D.P., Hyrich K.L., No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2010; 62: 3145-53.
94. Saad A.A., Ashcroft D.M., Watson K.D., Hyrich K.L., Noyce P.R., Symmons D.P., Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009; 11: R52.
95. Lord P.A., Farragher T.M., Lunt M., Watson K.D., Symmons D.P., Hyrich K.L., Predictors of response to anti-TNF therapy in ankylosing spondylitis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49: 563-70.
96. McErlane F., Foster H.E., Davies R., Lunt M., Watson K.D., Symmons D.P., Hyrich K.L., Biologic treatment response among adults with juvenile idiopathic arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2013; 52: 1905-13.
97. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al.Serious infection and mortality in patients with Crohn's disease: More than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409-22.
98. Gisondi P., Cazzaniga S., Chimenti S., et al.Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013; 27: e30-41.
99. Spandonaro F., Altomare G., Berardesca E., et al.Health-related quality of life in psoriasis: An analysis of Psocare project patients. G Ital Dermatol Venereol 2011; 146: 169-77.
100. Prignano F., Pescitelli L., Ricceri F., Lotti T., Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. J Eur Acad Dermatol Venereol 2010; 24: 555-60.
101. Nijsten T., Wakkee M., Psocare: Italy shows the way in postmarketing studies. Dermatology 2008; 217: 362-4.
102. Naldi L., Addis A., Chimenti S., et al.Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365-73.
103. Halpern M.T., Cifaldi M.A., Kvien T.K., Impact of adalimumab on work participation in rheumatoid arthritis: Comparison of an open-label extension study and a registry-based control group. Ann Rheum Dis 2009; 68: 930-7.
104. Kavanaugh A., Fleischmann R.M., Emery P., et al.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013; 72: 64-71.
105. Combe B., Landewe R., Lukas C., et al.EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45.
106. Epis O.M., Giacomelli L., Deidda S., Bruschi E., Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 2013; 12: 839-41.
107. Nusslein H.G., [How early would we really administer biologics?]. Z Rheumatol 2012; 71: 838-9.
108. Bouguen G., Levesque B.G., Feagan B.G., et al.Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clin Gastroenterol Hepatol 2013; pii: S1542-3565.
109. Kooloos W.M., de Jong D.J., Huizinga T.W., Guchelaar H.J., Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007; 12: 125-31.
110. Morales-Lara M.J., Canete J. D., Torres-Moreno D., et al.Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012; 79: 591-6. Bone Spine 2012; 79: 591-6.